Results 151 to 160 of about 77,108 (288)

Complete lymph node dissection versus selective lymph node extirpation in melanoma patients with nodal macrometastasis and adjuvant systemic therapy

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Complete lymph node dissection (CLND) is the standard of care in patients with regional nodal melanoma macrometastasis. However, evidence on surgical procedures in the era of adjuvant systemic therapies is lacking. Patients and Methods This retrospective multi‐center study included stage IIIB–D melanoma patients with ...
Kristine E. Mayer, Jessica C. Hassel, Jannik Sambale, Michael Erdmann, Mihaela‐Anca Sindrilaru, Julia Oberschmied, Alexander Thiem, Dirk Tomsitz, Jana Knuever, Max Schlaak, Carola Berking, Christian Posch, Tilo Biedermann, Oana‐Diana Persa   +13 more
wiley   +1 more source

Addressing current challenges in cancer immunotherapy with mathematical and computational modeling

, 2017
The goal of cancer immunotherapy is to boost a patient's immune response to a tumor. Yet, the design of an effective immunotherapy is complicated by various factors, including a potentially immunosuppressive tumor microenvironment, immune-modulating ...
Adler, Adam J., Konstorum, Anna, Laubenbacher, Reinhard, Vella, Anthony T.   +3 more
core   +1 more source

Neoadjuvant therapy in skin cancer: current evidence and future perspectives

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary The development of immune checkpoint inhibitors and targeted therapies has fundamentally changed the treatment of cutaneous malignancies, especially in squamous cell carcinoma, melanoma, and Merkel cell carcinoma. The latest neoadjuvant approaches have shown promising results in locally advanced stages.
Lea Daniello, Johannes Kleemann, Bastian Schilling   +2 more
wiley   +1 more source

Targeting the microbiota‐miRNA‐protease axis: A new therapeutic avenue in melanoma

The FEBS Journal, EarlyView.
Modulation of extracellular matrix (ECM) turnover is central to melanoma progression and metastasis, driven largely by ECM proteases. This review highlights the epigenetic regulation of ECM proteases by microRNAs and their roles in melanoma growth, invasion, and immune modulation.
Elias N. Katsoulieris, Paraskevi Ioannou, Nikolaos A. Afratis   +2 more
wiley   +1 more source

Clinical Outcomes of Reduced‐Dose Cabozantinib as Third‐ or Later‐Line Therapy After Immune Checkpoint Inhibitors in Advanced Hepatocellular Carcinoma: A Real‐World Study

Hepatology Research, EarlyView.
In this real‐world post‐ICI setting, cabozantinib demonstrated meaningful clinical activity even at reduced doses, with disease control achieved in nearly half of patients. Importantly, preserved liver function (Child–Pugh class A) was the only determinant of both disease control and overall survival.
Teiji Kuzuya, Hisanori Muto, Yoshihiko Tachi, Mizuki Ariga, Sayaka Morisaki, Gakushi Komura, Takuji Nakano, Hiroyuki Tanaka, Kazunori Nakaoka, Eizaburo Ohno, Kohei Funasaka, Mitsuo Nagasaka, Ryoji Miyahara, Yoshiki Hirooka   +13 more
wiley   +1 more source

Efficacy and Safety of Second‐Line Lenvatinib After First‐Line Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma

Hepatology Research, EarlyView.
ABSTRACT Background There is a paucity of data regarding the efficacy and safety of lenvatinib as a second‐line treatment following first‐line combination immunotherapy with durvalumab and tremelimumab (Dur + Tre). Methods This retrospective multicenter study included 14 patients with unresectable hepatocellular carcinoma who received lenvatinib after ...
Ryoichi Miura, Tomokazu Kawaoka, Saki Sueda, Aiko Tanaka, Kou Hashimoto, Tomoaki Emori, Yasutoshi Fujii, Hatsue Fujino, Atsushi Ono, Eisuke Murakami, Daiki Miki, Shinsuke Uchikawa, Nami Mori, Keiji Tsuji, Yosuke Suehiro, Keiichi Masaki, Michihiro Nonaka, Kenji Yamaoka, Yoshio Katamura, C. Nelson Hayes, Masataka Tsuge, Shiro Oka   +21 more
wiley   +1 more source

Cutaneous Immune‐Related Adverse Events and Efficacy of Immune Checkpoint Inhibitors for Patients With Advanced Solid Organ Malignancies

International Journal of Dermatology, EarlyView.
ABSTRACT Introduction Immune checkpoint inhibitors (ICIs) have significantly improved outcomes for patients with advanced solid tumors. While low‐grade immune‐related adverse events (irAEs) are associated with prolonged survival, high‐grade irAEs have been associated with poorer survival. Cutaneous immune‐related adverse events (cirAEs) affect up to 20%
David O'Reilly, Gregg Murray, Orla M Fitzpatrick, Hebatalla Ismail, Gavin P Dowling, Gargi Roy, David Synnott, Maggie O'Connor, Bryan T Hennessy, Oscar Breathnach, Liam Grogan, Megan Greally, Adrian Murphy, Patrick G Morris, Karen Eustace, Muireann Roche, Stephen Madden, Jarushka Naidoo   +17 more
wiley   +1 more source

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

New England Journal of Medicine, 2011
C. Robert, L. Thomas, I. Bondarenko, S. O'Day, J. Weber, C. Garbe, C. Lebbé, J. Baurain, A. Testori, J. Grob, N. Davidson, J. Richards, M. Maio, A. Hauschild, W. Miller, P. Gascón, M. Lotem, K. Harmankaya, R. Ibrahim, S. Francis, Tai-Tsang Chen, R. Humphrey, A. Hoos, J. Wolchok   +23 more
semanticscholar   +1 more source

Nivolumab plus ipilimumab in advanced melanoma.

New England Journal of Medicine, 2013
J. Wolchok, H. Kluger, M. Callahan, M. Postow, N. Rizvi, A. Lesokhin, N. Segal, C. Ariyan, R. Gordon, Kathleen Reed, M. Burke, A. Caldwell, S. Kronenberg, B. Agunwamba, Xiaoling Zhang, I. Lowy, H. Inzunza, W. Feely, C. Horak, Q. Hong, A. Korman, J. Wigginton, A. Gupta, M. Sznol   +23 more
semanticscholar   +1 more source

Exceptional therapeutic benefit of imatinib in cKIT‐mutated mucosal melanoma followed by a KIT mutation loss

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Hannah Zillikens, Corinna Scheib, Vicky Peller, Christina Müller, Sebastian Bauer, Ina Pretzell, Klaus Griewank, Antje Sucker, Eva Hadaschik, Felicitas Guntrum, Sven Holger Baum, Alexander Roesch, Selma Ugurel, Dirk Schadendorf, Lisa Zimmer, Elisabeth Livingstone   +15 more
wiley   +1 more source